Genetic markers for ovarian damage after chemo
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This study is looking for genetic markers that may help predict how chemotherapy affects the ovaries. It's for women who had breast cancer or lymphoma, froze their ovarian tissue before treatment, and finished that treatment at least 6 months ago.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were between 18 and 38 years old when you had ovarian tissue frozen.
- You had breast cancer or lymphoma.
- You finished your cancer treatment at least 6 months ago.
- You had no chemotherapy or radiation before the tissue freezing.
- You are not on hormone therapy that stops ovarian function (like GnRH analogs).
- You do not have certain genetic conditions (like BRCA mutations or Fragile X) or a family history of early menopause.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
This study looks at DNA changes to understand the cause of premature ovarian insufficiency (early menopause). It may help clarify what’s happening in your body and guide future care.
This trial compares two methods of preserving a woman's fertility before cancer treatment: freezing eggs alone versus freezing both eggs and ovarian tissue. The goal is to help women who may lose fertility due to chemotherapy or radiation keep their options open for having biological children in the future.
This study looks at genetic changes in ovarian cancer to find possible targeted treatments. It may help you if you have certain types of ovarian cancer and are seeking more personalized care.
This study looks at freezing (cryopreserving) ovarian tissue in people who are at risk of early menopause because of cancer treatment or surgery. It may help preserve natural hormone function and possible future fertility for those who cannot or do not want to freeze eggs or embryos.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.